Abiraterone Acetate 250mg

Abiraterone Acetate 250mg

Product Details:

  • Drug Type Specific Drug
  • Ingredients ABIRATERONE 250
  • Physical Form Tablets
  • Function Cancer Treatment
  • Dosage Prostate Cancer Metastatic castration-resistant prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic castration-resistant prostate cancer (CRPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Yonsa Indicated in combination with methylprednisolone for the treatment of patients with metastatic CRPC 500 mg (four 125-mg tablets) PO qDay in combination with methylprednisolone 4 mg PO BID Metastatic high-risk castration-sensitive prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer (CSPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Dosage Modifications Strong CYP3A4 inducers Coadministration with strong CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital): Avoid if possible; if strong CYP3A4 inducer must be administered, increase abiraterone dosage frequency of abiraterone Reduce dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued Yonsa Increase from 500 mg qDay to 500 mg BID Zytiga Increase from 1000 mg qDay to 1000 mg BID Hepatic impairment (Zytiga) Baseline LFTs Mild (Child-Pugh A): No dosage adjustment necessary Moderate (Child-Pugh B): Reduce starting dose to 250 mg PO qDay; monitor ALT, AST, and bilirubin prior to start of treatment, qWeek for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment, discontinue abiraterone and do not retreat patients Severe (Child-Pugh C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN: Interrupt treatment; reinitiate at reduced dose of 750 mg PO qDay following return of LFTs to baseline or to AST/ALT ≤2.5x ULN and total bilirubin ≤1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs at 750 mg/day, may restart at 500 mg/day (after LFTs decrease as above) If hepatoxicity recurs at reduced dose of 500 mg/day, discontinue treatment Permanently discontinue treatment for patients who develop a concurrent elevation of ALT >3x ULN and total bilirubin >2x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation Hepatic impairment (Yonsa) Baseline Moderate (Child-Pugh Class B): Reduce 125 mg PO qDay; monitor ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment: Discontinue treatment and do not retreat patients with abiraterone Severe (Child-Pugh Class C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN): Interrupt treatment; restart at a reduced dose of 375 mg qDay following return of liver function tests to the patient’s baseline or to AST and ALT ≤2.5x ULN and total bilirubin ≤1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs on 375 mg/day, may be restart aeduced dose of 250 mg/day (after LFTs decrease as above) I
  • Suitable For Aged Person, Adults
  • Quantity 5 Boxes
  • Supply Ability : 50 Bottle Per Day
259.59-273.26 USD ($)/Bottle
X

Price And Quantity

  • 259.59-273.26 USD ($)/Bottle
  • 3 Bottle

Product Specifications

  • ROOM TEMP. 10 -30 C
  • 5 Boxes
  • Prostate Cancer Metastatic castration-resistant prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic castration-resistant prostate cancer (CRPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Yonsa Indicated in combination with methylprednisolone for the treatment of patients with metastatic CRPC 500 mg (four 125-mg tablets) PO qDay in combination with methylprednisolone 4 mg PO BID Metastatic high-risk castration-sensitive prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer (CSPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Dosage Modifications Strong CYP3A4 inducers Coadministration with strong CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital): Avoid if possible; if strong CYP3A4 inducer must be administered, increase abiraterone dosage frequency of abiraterone Reduce dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued Yonsa Increase from 500 mg qDay to 500 mg BID Zytiga Increase from 1000 mg qDay to 1000 mg BID Hepatic impairment (Zytiga) Baseline LFTs Mild (Child-Pugh A): No dosage adjustment necessary Moderate (Child-Pugh B): Reduce starting dose to 250 mg PO qDay; monitor ALT, AST, and bilirubin prior to start of treatment, qWeek for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment, discontinue abiraterone and do not retreat patients Severe (Child-Pugh C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN: Interrupt treatment; reinitiate at reduced dose of 750 mg PO qDay following return of LFTs to baseline or to AST/ALT ≤2.5x ULN and total bilirubin ≤1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs at 750 mg/day, may restart at 500 mg/day (after LFTs decrease as above) If hepatoxicity recurs at reduced dose of 500 mg/day, discontinue treatment Permanently discontinue treatment for patients who develop a concurrent elevation of ALT >3x ULN and total bilirubin >2x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation Hepatic impairment (Yonsa) Baseline Moderate (Child-Pugh Class B): Reduce 125 mg PO qDay; monitor ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment: Discontinue treatment and do not retreat patients with abiraterone Severe (Child-Pugh Class C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN): Interrupt treatment; restart at a reduced dose of 375 mg qDay following return of liver function tests to the patient’s baseline or to AST and ALT ≤2.5x ULN and total bilirubin ≤1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs on 375 mg/day, may be restart aeduced dose of 250 mg/day (after LFTs decrease as above) I
  • Specific Drug
  • Cancer Treatment
  • Aged Person, Adults
  • ABIRATERONE 250
  • Tablets

Trade Information

  • Cash in Advance (CID)
  • 50 Bottle Per Day
  • 2 Week
  • 1*120 TAB/BOTT
  • Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia
  • All India

Product Description

USES OF ZECYTE TABLET

Prostate cancer

BENEFITS OF ZECYTE TABLET

In Prostate cancer

Prostate gland is a small walnut-sized gland that produces a fluid called seminal fluid that nourishes and transports sperms in males. The most common symptom of prostate cancer is difficulty with urination, but sometimes there are no symptoms at all. Zecyte 250mg Tablet decreases or stops the growth of cancer cells by decreasing the amount of testosterone (natural hormone in males) in men. This also relieves difficulty in passing urine and makes it easier for you to urinate.

SIDE EFFECTS OF ZECYTE TABLET

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you're worried about them

Common side effects of Zecyte
  • Edema (swelling)
  • Vomiting
  • Decreased potassium level in blood
  • Decreased white blood cell count
  • Fatigue
  • Increased liver enzymes
  • Anemia (low number of red blood cells)
  • Urinary tract infection
  • Diarrhea
  • High blood pressure
  • Cough
  • Hypercholesterolemia (high cholesterol)
  • Joint swelling
  • Increased levels of blood fat
  • Altered blood sugar level
HOW TO USE ZECYTE TABLET

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Zecyte 250mg Tablet is to be taken empty stomach.

HOW ZECYTE TABLET WORKS

Zecyte 250mg Tablet is an anticancer medication. It works by preventing androgen (male hormone) production in man. This is done by inhibiting an enzyme (CYP17) that is responsible for the production of androgen. This is how it slows down the growth of prost

SHRESTHA GLOBAL PHARMA

* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.



Back to top
SHRESTHA GLOBAL PHARMA All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Ltd.(Terms of Use)
Developed and Managed by Infocom Network Ltd.